EyeCRO are Experts in preclinical efficacy studies in ophthalmic retinopathy, pharmacokinetics, both in vivo and in vitro for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in retina preclinical efficacy, oxygen-induced retinopathy, and ophthalmic pharmacokinetics for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in Laser CNV, Retina preclinical efficacy, and Ophthalmic toxicology for clinical and precise formulation services.

Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research

MiDROPS™

The Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.

 

In-Vivo

EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Detecting diabetic eye disease with machine learning

Diabetic retinopathy — an eye condition that affects people with diabetes — is the fastest growing … Read More

Cause of inflammation in diabetes identified

Inflammation is one of the main reasons why people with diabetes experience heart attacks, strokes, … Read More

Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models

Experimental and clinical data suggest that pro-angiogenic, pro-inflammatory and mitogenic cytokine … Read More

More News

Saturday, December 3rd, 2016 at 4:17am
RT @Alnylam: Prior to #ASH16, learn how #RNAi therapeutics represent potential new class of medicines. Science ‘splainer here: https://t.co…
Tuesday, November 29th, 2016 at 3:51am
The many ways lasers help us see the world more clearly - BBC News https://t.co/TYJZF3Hhck
Ophthalmic Contract Research